Advanced pharmaceutical intermediates often contain most of the structural complexity of the final active ingredient. Their role is to provide a controlled platform for the final stages of molecular assembly, protection, deprotection, and purification.
Boc-Risdiplam (CAS 2133298-74-3) is a representative example. It contains the principal heterocyclic framework of risdiplam and retains a tert-butoxycarbonyl protecting group on the diazaspiro unit.
For pharmaceutical process developers, this makes it an advanced protected intermediate rather than a simple starting material.
Product Identity and Molecular Structure
The full chemical name is:
Key specifications:
- · Product Name: Boc-Risdiplam
- · CAS Number: 2133298-74-3
- · Molecular Formula: C₂₇H₃₁N₇O₃
- · Molecular Weight: 501.59 g/mol
- · Synonyms: Risdiplam intermediate; tert-butyl 7-(substituted heteroaryl)-4,7-diazaspiro[2.5]octane-4-carboxylate
- · Typical Product Grade: 98% as listed in the supplied product specification
PubChem and commercial reference data confirm the CAS number, molecular formula, and molecular weight.
What Makes This an Advanced Intermediate?
Boc-Risdiplam already contains several key structural elements found in risdiplam:
- · A 2,8-dimethylimidazo[1,2-b]pyridazine fragment
- · A pyrido[1,2-a]pyrimidinone framework
- · A 4,7-diazaspiro[2.5]octane structural unit
- · A Boc-protected nitrogen functionality
The spirocyclic unit is particularly important because it provides a defined three-dimensional framework within the molecule.
The Boc group temporarily protects one nitrogen atom. In a suitable synthetic sequence, removal of this protecting group can provide the corresponding free nitrogen functionality required for the next stage or final API preparation.
Connection to Risdiplam Development
Risdiplam is an orally administered medicine used to treat spinal muscular atrophy. It works by modifying SMN2 pre-mRNA splicing, increasing production of functional survival motor neuron protein.
Boc-Risdiplam is relevant to the synthesis of this API because it contains the assembled heterocyclic and spirocyclic framework in a protected form.
However, the precise final conversion sequence depends on the manufacturing route. A supplier or buyer should verify the intended route and intermediate specifications rather than assume that every process uses an identical deprotection or finishing step.
Patent literature describes alternative routes and intermediates for preparing risdiplam, demonstrating that process design can vary between synthetic approaches.
Why the Spirocyclic Framework Deserves Attention
The 4,7-diazaspiro[2.5]octane group is more than a structural label. Spirocyclic compounds can provide a compact three-dimensional arrangement that differs from conventional linear or fused-ring structures.
In medicinal chemistry, such frameworks can influence:
- · Molecular conformation
- · Spatial orientation of substituents
- · Hydrogen-bonding patterns
- · Physicochemical properties
- · Interactions with biological targets
For Risdiplam synthesis, the spirocyclic unit forms part of the advanced molecular architecture. Its integrity and substitution pattern must therefore be maintained throughout subsequent processing.
Quality Control for Boc-Risdiplam
Because this is an advanced intermediate with a complex heterocyclic structure, procurement should include a detailed analytical review.
Identity: Confirm CAS 2133298-74-3, molecular formula, and structure.
Assay: Evaluate chromatographic purity using a suitable validated method.
Related substances: Monitor structurally related impurities and potential degradation products.
Protecting-group integrity: Confirm that the Boc group remains intact before the intended deprotection step.
Residual solvents and water: Assess these parameters according to the downstream process requirements.
Batch consistency: Compare impurity profiles and analytical results across batches.
A high assay result is useful, but it should be considered together with the full impurity and characterization package.
SHLZ Pharma: From Intermediate Development to Scale-Up
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. focuses on the development, customization, and production of pharmaceutical intermediates and APIs.
According to its company profile, SHLZ Pharma operates an R&D laboratory and pilot production workshops, with capabilities covering laboratory development, process optimization, and scale-up. The company reports customization support from gram to kilogram scale and larger pilot/factory production capabilities.
For customers sourcing advanced intermediates such as Boc-Risdiplam, these capabilities can be relevant when discussing route-specific quality requirements, analytical methods, and supply planning.
Conclusion
Boc-Risdiplam (CAS 2133298-74-3) is an advanced protected intermediate associated with Risdiplam synthesis. It has the molecular formula C₂₇H₃₁N₇O₃ and a molecular weight of 501.59 g/mol.
Its main structural features include the imidazopyridazine and pyridopyrimidinone fragments, a diazaspiro framework, and a Boc-protected nitrogen atom. For buyers, the key qualification points are identity, assay, impurity profile, protecting-group integrity, and batch consistency.
Post time: Nov-13-2026
